Amyotrophic lateral sclerosis (ALS) is a progressively debilitating disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of…
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging…
Hormonal therapy is the cornerstone of drug treatment for prostate cancer in all patient populations. Abiraterone and Xtandi (Pfizer / Astellas Pharma) dominate the metastatic castrate-resistant…
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
Sickle cell disease (SCD) is a rare genetic blood disorder characterized by polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to various…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Since the emergence of the…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. Treatments are needed that can…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…